Live Breaking News & Updates on Vaccine Candidates

Stay updated with breaking news from Vaccine candidates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Researchers develop potential vaccine against antibiotic-resistant enterococci

Researchers develop potential vaccine against antibiotic-resistant enterococci
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Theresa Maria Wagner , Theresa Wagner , Jan Fredrik Frantzen , Arctic University Of Norway , International Journal Of Molecular Sciences , Ludwig Maximilian University , Uit The Arctic University , Arctic University , International Journal , Enterococcal Membrane Vesicles , Vaccine Candidates , Molecular Sciences ,

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus. The data were presented during the World Vaccine Congress, West Coast conference, bein ....

Mark Newman , Santa Clara , National Institute Of Allergy , Company Contact , University Of Texas Medical Branch At Galveston , Department Of Microbiology , Preclinical Services , World Vaccine Congress , Geovax Labs Inc , Nonhuman Primates Observed , Lethal Challenge , Geovax Labs , West Coast , Jason Comer , Associate Professor , Texas Medical Branch , Geovax Chief Scientific Officer , National Institute , Infectious Disease , Vax Labs , Relations Contact , Preclinical Studies , Marburg Virus , Vaccine Candidates , Infectious Diseases , Ebola Virus ,

Pfizer, BioNtech say flu-COVID shot generates strong immune response in trial

"This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices," Annaliesa Anderson, Pfizer's head of vaccine research and development, said in a statement. In the trial, the vaccine candidates were compared to a licensed influenza vaccine and the companies' updated COVID-19 vaccine given at the same visit. ....

Manas Mishra , Annaliesa Anderson , Savio Dsouza , Saviod Souza , Immune Response , Influenza Vaccine , Vaccine Candidates , Respiratory Diseases , Annaliesa Anderson , Vaccine Research And Development ,

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr ....

United States , New York , City Of , United Kingdom , Alexander Siebert , Kabeer Aziz , Zina Affas Besse , Limmatech Biologics , Franz Werner Haas , Camilla Petrycer Hansen , Hooft Van Huijsduijnen , Limmatech Bio , Novo Holding , Principal At Novo Holdings , Impact Fund , National Overview , Infective Resistance Impact Fund , Novo Holdings , Novo Nordisk Foundation , World Health Organization , Trophic Communications , United States Centers For Disease , Adjuvant Capital , Affas Besse , Deputy Head , Private Equity ,

BioNTech partners with CEPI to advance development of mpox vaccine

BioNTech would initiate an early-to-mid stage trial for the vaccine program BNT166 to prevent mpox, a viral illness that causes skin rashes and could be transmitted to humans through physical contact. The vaccine candidates are based on the same messenger-RNA (mRNA) technology which has been used in its COVID shots developed with partner Pfizer. The partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) also aims to contribute to its mission to accelerate development of vaccines to be ready for regulatory authorization and manufacturing at scale within 100 days of recognition of pathogen with pandemic potential. ....

Nivedita Bhattacharjee , Mrigank Dhaniwala , Sriparna Roy , Coalition For Epidemic Preparedness Innovations , Epidemic Preparedness Innovations , Vaccine Candidates , Global Coalition , Coalition For Epidemic Preparedness Innovations ,